14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Fair Lawn, New Jersey, United States, 07410
- TKL Research Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female, 18-70 years of age, in general good health
- normal skin
- free of any systemic or dermatologic disorder which, in the opinion of the investigative personnel, will interfere with the study results or increase the risk of adverse events
- of any skin type or race providing the skin pigmentation will allow discernment of erythema
- agree to complete a medical history and concomitant medication form
- read, understand and sign informed consent
Exclusion Criteria:
- have any visible skin disease at the study site which, in the opinion of the investigative personnel, will interfere with the evaluation
- are receiving systemic or topical drugs or medication which, in the opinion of the investigative personnel, will interfere with the study results
- have psoriasis and/or active atopic dermatitis/eczema
- have a known sensitivity to cosmetics, skin care test articles, or topical drugs as related to the test article being evaluated
- are females who are pregnant or breastfeeding or become pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Healthy subject
Healthy subjects exposed to Trojan "Chameleon" Personal Lubricant applied by occlusive patch
|
silicone base with sensate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale
Time Frame: 14 days
|
14 days
|
|
Number of Subjects That Showed Edema Based on the 5 Point Scoring Scale
Time Frame: 14 days
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: John Dosik, MD, TKL Research, Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ST-7611
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.